TY - JOUR
AU - Alfonso-Pierola,A.
AU - Martinez-Cuadrón,D.
AU - Rodríguez-Veiga,R.
AU - Gil,C.
AU - Martínez-Sánchez,P.
AU - Bernal,T.
AU - Benavente,C.
AU - Romero-Riquelme,M.A.
AU - Serrano-Lopez,J.
AU - Bergua,J.M.
AU - García-Boyero,R.
AU - Tormo,M.
AU - Herrera,P.
AU - Sossa-Melo,C.L.
AU - Pérez-Simon,J.A.
AU - Rodríguez-Medina,C.
AU - Bass-Maturana,M.F.
AU - López-Lorenzo,J.L.
AU - Algarra-Algarra,L.
AU - Vidriales-Vicente,B.
AU - Pérez-Encinas,M.
AU - Barrios-García,M.
AU - Vives,S.
AU - Sayas-Lloris,M.J.
AU - Capurro,M.
AU - Hidalgo,S.
AU - Olave,M.
AU - Cuervo-Lozada,D.
AU - Lavilla-Rubira,E.
AU - Casado,F.
AU - Mena-Durán,A.
AU - Valero-Nuñez,M.
AU - Casado-Calderón,S.
AU - Balerdi,A.
AU - Torres,V.
AU - Fernández,R.
AU - Noriega,V.
AU - Stevenazzi,M.
AU - Labrador,J.
AU - León-Maldonado,P.
AU - de Rueda-Ciller,B.
AU - Arce-Fernández,O.
AU - Amigo,M.L.
AU - Raposo-Puglia,J.Á.
AU - Solé,M.
AU - Boluda,B.
AU - Ayala,R.
AU - Barragán,E.
AU - Montesinos,P.
T1 - Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry
LA - eng
PY - 2025/11/01/
SP - 2686
EP - 2696
T2 - Leukemia
SN - 1476-5551
VL - 39
IS - 11
PB - Springer Nature
AB - While allogeneic stem cell transplantation (allo-SCT) is the preferred consolidation for high and most intermediate-risk acute myeloid leukemia (AML) patients in first remission, the role of autologous SCT (auto-SCT) vs. chemotherapy (CT) when allo-SCT is not feasible or indicated, remains controversial. We conducted a real-world, retrospective cohort study using the PETHEMA AML registry to compare auto-SCT and CT. Multivariate Cox regression and propensity score matching (PS-matching) were used to adjust for confounding factors. A total of 1272 patients in first remission and who received 2 consolidation courses were included (615 receiving additional CT cycles and 657 undergoing auto-SCT). Overall, 78.08% of auto-SCT patients were diagnosed before 2017, compared to 38.11% in the CT cohort (p < 0.001). In the overall cohort, auto-SCT was associated with significantly prolonged overall survival (OS) (HR: 0.73, p < 0.001) and relapse-free survival (RFS) (HR: 0.73, p < 0.001). This benefit was particularly evident in patients ≤65 years, those with normal karyotype, and FLT3-ITD negativity. In the PS-matched cohort, the RFS advantage persisted (HR: 0.80, p = 0.092), but OS differences were not statistically significant (HR: 0.91, p = 0.563). The role of auto-SCT in the genomic and targeted agent era should not be discarded.
DO - 10.1038/S41375-025-02744-X
UR - https://portalcientifico.uah.es/documentos/6922228b621d0957276dde5b
DP - Dialnet - Portal de la Investigación
ER -
